Key Highlights
- CurveBeam AI Limited (ASX:CVB) has received its first order for HiRise weight-bearing CT systems in China, for four units.
- The order came from distribution partner Weiying/Wego Orthopedics, following NMPA clearance of the HiRise system.
- The distribution agreement covers China, Hong Kong, Macau and Taiwan and was announced on 30 October 2025.
- The company expects to receive a A$1 million milestone Investment at A$0.405 per share during the current quarter.
CurveBeam AI Limited (ASX:CVB) has received its first order for HiRise weight-bearing CT systems for the Chinese market, with four units ordered by its distribution partner Weiying/Wego Orthopedics. The company, which develops point-of-care CT imaging equipment and AI-enabled clinical assessment software, announced the order on 19 November 2026. It is the first commercial order under the company’s long-term exclusive distribution arrangement covering the Greater China region.
The Order and Its Background
The order followed National Medical Products Administration clearance of HiRise, which the company announced on 13 October 2026. HiRise performs weight-bearing scans of the lower limb under natural bilateral loading, as well as traditional non-weight-bearing CT scans, giving orthopaedic clinicians three-dimensional images in a standing position.
The exclusive distribution agreement with Weiying was announced on 30 October 2025 and covers China, Hong Kong, Macau and Taiwan. The company says the agreement provides a framework for commercialisation in the region, with product sales expected to depend on market adoption over time.
Commercial Scope and Capital Milestone
Chief Executive Greg Brown described the order as an important commercial step and said it moves the Partnership from agreement to commercial execution. The company has not disclosed the value of the four systems in the announcement, so the order’s financial contribution cannot be assessed from the release.
CurveBeam also expects to receive its next milestone investment of A$1 million at an issue price of A$0.405 per share this quarter. The company notes that international banking processes can occasionally cause delays, though it still expects receipt within the quarter.
Company Profile and Operations
CurveBeam AI describes itself as a developer, manufacturer and seller of specialised CT scanners and AI-based SaaS clinical assessment tools for musculoskeletal conditions. The company has more than 70 employees, with its corporate office and AI and IP functions in Melbourne and its global operations headquarters in Hatfield, Pennsylvania, in the United States.
The company’s announcement includes standard forward-looking statement cautions and notes that it does not intend to update those statements except as required by law.
Looking Ahead
The next visible points will be receipt of the A$1 million milestone investment this quarter and any further orders from Weiying/Wego. Investors will be watching how quickly the four systems are introduced into clinical use and whether the company reports further orders as market adoption develops.






Please wait processing your request...